Podcasts about Hackensack University Medical Center

Kelly Nierstedt never planned to lead a hospital. She is a first-generation college graduate who worked on Wall Street out of high school, went to nursing school as a second career, and wanted nothing more than to be the best labor and delivery nurse she could be. Then the taps on the shoulder started. Take on this project. Take on this unit. Take on another. Today, Kelly is the president of Orlando Health Orlando Regional Medical Center, one of the largest and most complex hospitals in Florida and home to the region's Level 1 Trauma Center — and senior vice president of the Orlando Region. She got there without an MBA, without a finance background, and without ever checking all the boxes first. In this episode of Inspiring Women, Laurie McGraw sits down with Kelly to trace the path from the bedside at Hackensack University Medical Center, to leading OSF Healthcare Children's Hospital of Illinois in Peoria — where she built a care-closer-to-home model so families no longer had to drive four hours to Chicago — to becoming the inaugural president of Orlando Health Winnie Palmer Hospital for Women and Babies, one of the busiest delivery hospitals in the nation. Then came the second yes: leading the adult flagship hospital, where the one thing they don't do is the one thing she was trained in. Laurie and Kelly met at the Women Business Leaders Conference, where Kelly spoke about complexity in healthcare today. Topics Covered: - From Wall Street in the late 80s to nursing school on loans — a second career with no roadmap - Why Kelly said yes to every tap on the shoulder, and the Plan B mindset that made her fearless - Why women wait to check every box before saying yes — and why she never did - The move from New Jersey to Peoria, Illinois, and convincing a resistant leadership team with data - Recruiting physicians to middle America — and why they stayed - Interviewing for the Winnie Palmer presidency while on vacation in Fort Lauderdale - Why she puts on scrubs in every role: answering phones, filling water jugs, showing the team she cares - Walking into a Level 1 Trauma Center as a mom-baby nurse — and why not knowing made her a better leader - Four years in, every member of her original team is still there or has been promoted - "The keeper of the culture": what a hospital president actually does - Why her team members — not patients — are the most important people in the building - Move fast, fail fast: why healthcare's caution can leave patients behind - Transforming a large, tactical board into a smaller, strategic, deliberately diverse one - The patient suicide that shook her — and the board meeting where she cried, said "I'm not doing well," and was met with open arms - Her advice to senior women executives: you're not perfect, no one expects you to be, and vulnerability will serve you Kelly's story is proof that the path to the top doesn't require a pedigree — it requires the courage to say yes before you feel ready, the humility to learn from the experts around you, and the heart to never lose sight of who you're serving. As she puts it: "We're not perfect. We're just people trying to do a good job every day. Be open about that, and you will be just fine." Inspiring Women is hosted by Laurie McGraw, Chief Commercial Officer at Transcarent, former SVP of the American Medical Association, former President of Allscripts, and a 30-year healthcare executive committed to advancing women into leadership. Full episode wherever you get your podcasts. Subscribe so you never miss a conversation.

"When we think of drug interactions, specifically, the National Cancer Institute actually defines this as a change in the way a drug acts in the body when taken with certain other drugs, herbals, or foods or when taken with certain medical conditions. Drug interactions may cause the drug to either be more or less effective or cause effects on the body that are not expected," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about interaction pathways. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD), including 30 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by July 10, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge related to drug interactions in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series ONS Voice articles: Are Your Patients Taking Herbs That May Interact With Their Cancer Drugs? Pharmacogenomics Testing Helps to Ensure That Effective Therapy Is Safe Therapy Use of Herbal Products Carries Risk for Drug Interactions, but Patient–Clinician Knowledge, Communication Remain Low What the Research Says About Drug Interactions and Medical Cannabis ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS Huddle Cards: DPYD Gene and DPD Enzyme Pharmacogenomics ONS Oral Anticancer Medication Toolkit American Journal of Nursing articles: Understanding Pharmacokinetics: Part1: Drug Absorption Understanding Pharmacokinetics: Part 2: Drug Distribution Understanding Pharmacokinetics: Part 3: Drug Metabolism Understanding Pharmacokinetics: Part 4: Drug Elimination Journal of Nuclear Medicine Technology articles: Pharmacology, Part 1: Introduction to Pharmacology and Pharmacodynamics Pharmacology, Part 2: Introduction to Pharmacokinetics ClinPGx To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "One of the most notable food interactions that interacts with many different medications is actually grapefruit or grapefruit juice. This is known to be a very strong CYP3A4 inhibitor. … A lot of medications are metabolized through the CYP3A4 pathway. By inhibiting the effect of these enzymes, that can actually increase and significantly increase the concentrations of these therapies. It's not an interaction that's just limited to grapefruit. I would say grapefruit being in the food interaction is kind of one of the most well-known, but it can also be seen with other foods as well, like pomegranate juice or a very specific type of orange called Seville oranges. And this is really just due to the presence of a substance called furanocoumarins." TS 6:12 "There have been a pretty large number of genes identified that are responsible for coding some of those common enzyme families that I had been discussing, some of those CYP450 enzymes, but other enzymes as well that are important for drug metabolism. Based on the type of gene, there could be some different categories where patients are normal metabolizers, intermediate metabolizers, or poor metabolizers. There are some other categories as well based on the type of gene we're looking at. And that can ultimately impact the way you are able to metabolize drugs." TS 15:56 "Another common [geneotypic variation] that we always think about in oncology is G6PD, where if someone has G6PD deficiency, these patients can be at greater risk of hemolytic anemias when receiving certain types of therapies. Dapsone and rasburicase are just a couple that have been associated with this risk." TS 17:50 "One of the big concerns is always polypharmacy. Our patients truly can be on a lot of medications. In the field that I work in, transplant, patients automatically from their transplant are on many, many different medications that can potentially predispose them to side effects. … But I think when it comes to the many drug interactions that may flag in these situations, we really have to look at the patient as a whole. Like, how long have these patients been on these therapies? Are they having side effects? Have they been on the combination for a very long time now? So I think that not just looking at the drug reference and seeing that there are like 10 different interactions flagged, but really assessing your patient as a whole can be very important—just because real-world practice, of course, is not black and white. It's often very gray, so it's just important to use clinical judgment in those scenarios." TS 26:10

Episode Summary What happens when a surgeon decides she's done being underpaid and undervalued — and refuses to sell her practice to private equity? She goes out of network. That's exactly what Dr. Sarah Bryczkowski did, and in this episode she walks us through every step of how she made it work. Dr. Bryczkowski is a robotic general surgeon in Somerset County, New Jersey and a partner at Somerset Surgical Specialists. After making partner in a private practice and realizing she was barely covering overhead as an in-network surgeon, she convinced her partners to take the leap out of network. Since September of last year, they've been operating entirely out-of-network — and they've never looked back. This episode breaks down a model that most physicians have heard about but don't fully understand. Sarah demystifies the billing process, explains what the No Surprises Act actually means for surgeons and patients, and talks honestly about the financial risks, the leap of faith, and what it finally feels like to get paid what you're worth. What You'll Learn in This Episode What "out of network" actually means — and why insurance companies don't want you to understand it How the No Surprises Act changed the game (for better and for worse) What balanced billing really is — and how it's used to scare patients away from out-of-network doctors How Independent Dispute Resolution (IDR) works and why surgeons are winning The billing workflow: from consult to arbitration (and why you won't see money for 3–6 months) How Dr. Bryczkowski convinced her skeptical partners to make the switch The partnership track reality — why making partner isn't always what you expect What the first year in an out-of-network practice actually looks like financially The metrics to watch so you're not flying blind on income Who this model is and isn't right for How to find a billing company and legal team you can trust Key Quotes "I'm doing quality surgery. I wanted to find a way to get paid what I'm worth for what I do — and the employed model didn't fit." "Balanced billing is a term insurance companies use to scare people away." "Even if I wasn't making money, I wouldn't want to be told what to do. It's worth it." "I don't have people problems, I have checklist problems." "You're sucking wind now, but as long as you've got the metrics, you know you're gonna be okay." "It's a journey of faith and challenge and courage — but it's so worth it." Resources Mentioned Somerset Surgical Specialists — somersetsurgical.com The No Surprises Act (2021) Independent Dispute Resolution (IDR) process Online directories for in-network/out-of-network physician lookup About Dr. Sarah Bryczkowski Dr. Sarah Bryczkowski is a robotic general surgeon and partner at Somerset Surgical Specialists in Somerset County, New Jersey. She trained at Hackensack University Medical Center, where she was first exposed to the out-of-network practice model. After several years in both employed and in-network private practice settings, she led her practice group to transition out of network — without selling to private equity. She specializes in complex robotic surgery including component separations, hiatal hernia repairs, and fundoplications.

"They are small, powerful little nuggets. They are actually small signaling proteins that our immune cells use to communicate. They really help regulate immune activation or inflammation and even the growth and survival of immune cells. When cytokines are used therapeutically in oncology, they help to stimulate immune cells such as T cells or natural killer cells to better recognize and attack cancer cells," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center of Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the cytokine drug class. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours (including 30 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 24, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with cancer require knowledge of cytokines to provide appropriate education and to safely administer related therapies. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis ONS Voice articles: FDA Approves Nogapendekin Alfa Inbakicept-Pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents Oncology Drug Reference Sheet: Motixafortide ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) and 2024 Drug Supplement Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy (second edition) Clinical Journal of Oncology Nursing article: Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Nursing Considerations What's Old Is New Again, Unfortunately ONS Symptom Interventions Colony-Stimulating Factors Including Biosimilars for At-Risk Patients for Prevention of Infection: General Platelet Growth Factors for Prevention of Bleeding National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Cytokines are actually among some of the earliest forms of immunotherapy used in the treatment of cancer, and it really goes back to the 1980s and the 1990s. We're talking therapies like interferon [alpha] or interleukin-2 that were used to stimulate the immune system, with the idea that they would recognize and attack cancer cells, particularly in diseases like metastatic melanoma and renal cell carcinoma. What made these therapies unique was that although the overall response rates were relatively modest, when patients did respond, those responses could be very durable and sometimes long lasting. And that observation was really important for the field of oncology, because it was part of the process that demonstrated that the immune system could potentially control cancer in really meaningful ways." TS 1:49 "One nice new example of an engineered cytokine is nogapendekin alfa inbakicept, which is quite the tongue twister to say. … This agent is really interesting because it's an engineered interleukin-15 receptor agonist that works on stimulating natural killer cells and CD8-positive T cells. And what makes this so interesting is that it's used in combination with a medication that probably some of us are familiar with—good old BCG—for patients specifically with invasive bladder cancer. The other really interesting thing about this new therapy is the fact that it is one of our first ones to be engineered in a combination fashion. So the nogapendekin alfa is combined with a receptor component that is called inbakicept. And what happens is it forms a complex to enhance signaling and prolong the activity of the cytokine." TS 7:50 "When you're looking at our therapeutic cytokines, those tend to produce larger-scale systemic inflammatory effects leading to much more global side effect reactions, while your supportive care cytokines are more commonly associated with either bone marrow stimulation effects or hematologic changes." TS 14:01 "Regardless of what type of cytokine therapy may you be using, across the board, early recognition of the symptoms and proactive supportive care are really important. And this is where many of our oncology nurses play such a critical role in identifying changes that are happening in real time to the patient's condition and helping to coordinate, relay information to the rest of the providing team so that timely interventions can occur for the best care of the patient." TS 18:01 "The other fascinating thing about these cytokines is that they're not being used as monotherapy anymore. They're now being looked at in combination with other therapies or even other immunotherapies like our checkpoint inhibitors. They're being looked at in the sense that they may be able to help expand and further activate immune cells that our current therapies rely on. And so it's really interesting that while cytokines were some of the earliest forms of cancer immunotherapy, they're now being reimagined as part of modern combination strategies designed to really further help enhance the immune responses against cancer." TS 29:08

"Headache is just a teeny piece of the puzzle," says Dr. Regina Krel, an insight that's at the heart of why migraine syndrome, one of the leading causes of disability worldwide, remains so persistently misunderstood. In this informative conversation with Raise the Line from Elsevier host Michael Carrese, Dr. Krel, the director of Headache Medicine at Hackensack University Medical Center, explains migraine as a storm that sensitizes the entire brain, not just the site of the headache, which explains the long list of symptoms people experience including sensitivity to light and sound, brain fog, fatigue and problems with balance. “The headaches can be severe, but it's the other symptoms that really kind of take over your whole body that make patients dysfunctional.” Dr. Krel also explains why migraine disproportionately impacts women in the prime of their working and caregiving years, and offers guidance for treating migraines in women, whose symptoms are commonly dismissed by non-specialists. Stay tuned to also learn about: The "migraine triangle"; Why stigma around migraine persists even in doctors' offices; New treatment options including neuromodulation devices. Mentioned in this episode: Headache Center at Hackensack University Medical Center If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

"You want to try to act quickly and be able to know what the pathways are for appropriate escalating when a patient is having symptoms that are reflective of cytokine release syndrome (CRS) or neurotoxicity. These toxicities are very manageable and treatable when recognized early. To summarize, choosing the right patient, knowing the toxicity profile for each product, and acting early is really what helps to prevent severe outcomes with chimeric antigen receptor (CAR) T-cell therapy," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about CAR T-cell immunotherapy. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 20, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to CAR T-Cell immunotherapy in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 267: Side-Effect Management for CAR T-Cell Therapy for Hematologic Malignancies Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome ONS Voice articles: A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities CAR T-Cell Therapy Programs Oncology Clinical Social Workers Add Layers of Support for Patients and Families During CAR T-Cell Therapy Studies Show Best Practices to Manage CAR T-Cell Therapies' irAEs and Improve Outcomes ONS Voice oncology drug reference sheet: Lisocabtagene Maraleucel Clinical Journal of Oncology Nursing articles: CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma CAR T-Cell Therapy: Updates in Nursing Management Nursing Considerations in Navigating Patients Receiving CAR T-Cell Therapy ONS book: Guide to Cancer Immunotherapy (second edition) ONS Huddle Cards: Chimeric Antigen Receptor T-Cell Therapy Cytokine Release Syndrome Immune Effector Cell–Associated Neurotoxicity Syndrome Immunotherapy Immuno-Oncology Learning Library American Society of Gene and Cell Therapy: Learning Center American Society for Transplantation and Cellular Therapy: Learning Center National Comprehensive Cancer Network home page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "CAR T-cell therapy combines an adoptive cell transfer with genetic engineering. And what that really means is that we are harvesting a patient's own T cells and then we engineer them with a synthetic receptor that helps them recognize that cancer. And all of this work has evolved through many decades of stepwise advances in how we design and activate the T cells. That led us to several landmark trials and ultimately the first CAR T-cell therapy approved by the U.S. Food and Drug Administration in 2017, which was tisagenlecleucel for pediatric and young adult patients that had acute lymphoblastic leukemia." TS 3:34 "If a patient has higher disease burden or an inflammatory biology, that does tend to correlate with higher toxicity risk. And then that might influence the way we monitor the patients who are getting the CAR T therapy. And then finally, baseline neurologic examinations, because neurotoxicity can occur with these agents. It's very important that we as a whole healthcare team really understand what the patient looks like at baseline to be able to determine if they're having any altered changes or confusion. If I had to summarize it, we want to confirm the target and make sure that we have the right CAR T product for the patient. We want to confirm that the patient, physiologically and mentally, is ready for the CAR T therapy." TS 10:53 "I think the two [toxicities] that every nurse will hear about almost immediately when talking about CAR T therapy are CRS or ICANS, which stands for immune effector cell–associated neurotoxicity syndrome. ... ICANS can either follow or even occur alongside CRS. And this can present as something as simple as just being slightly confused or altered, leading into progressively more severe elements such as word-finding difficulties, tremors, or changes in handwriting. Or even more severe cases that lead to seizures or decreased levels of consciousness. So, in this setting, neurologic assessments and knowing and understanding what your patient's baseline neurologic status is is so important. Those are really the two largest side effects that cross the board when it comes to CAR T therapies." TS 16:02 "In terms of the more practical aspects of administration, this is not a typical medication infusion. CAR T cells are living cells. So the way they are handled and administered is very specific. The majority of CAR T products are given as a single IV infusion. The cells come to us frozen either from a cellular lab or they will come from the pharmacy department. So those cells are typically thawed, and timing is of the essence. You really need to coordinate the timing of [thawing] to when they get infused to your patient. They tend to have a short shelf life once they're not frozen anymore." TS 26:34 "Now that therapy has, in many places, transitioned to be administered in the outpatient setting, education becomes absolutely critical. The patient is coming for their daily visit to clinic and then they're going home. And it's really up to the caregiver, who is usually not a nurse, who has to recognize early signs of toxicity. They need to be educated about what a fever is, what number constitutes a fever, what does confusion look like, what does hypotension look like? ... Do they have access to a thermometer? If you are asking them to look at blood pressure, do they have access to a blood pressure monitor? And sometimes those can be subtle things that might be overlooked. So, the emphasis in outpatient quality education is teaching those caregivers what to watch for, how to act quickly, and who to call immediately. You need to make sure that they have that information readily available if something happens." TS 30:55

In this “Leaders in Healthcare” edition of Lessons in Leadership, Steve Adubato and Mary Gamba are joined by Lisa Tank, MD, MBA, FACP, President and Chief Hospital Executive, Hackensack University Medical Center, about the future of healthcare leadership and trust in public health. Then, Steve and Mary are joined by Alyssa McCloud, PhD, Senior Enrollment … Continue reading Lessons in Leadership: Lisa Tank / Alyssa McCloud

This episode, recorded live at the Becker's 13th Annual CEO + CFO Roundtable, features Lisa Tank, President and Chief Hospital Executive, Hackensack University Medical Center, Hackensack Meridian Health. She discusses how her team is using AI, governance, and culture to enhance clinical outcomes, streamline operations, and strengthen patient trust.In collaboration with R1.

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

In today's episode, we had the pleasure of speaking with Pooja M. Phull, MD, a hematologist/oncologist at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, about emerging insights into the gut microbiome and its clinical relevance in multiple myeloma. Dr Phull discussed how microbial composition—particularly the presence of butyrate-producing bacteria—may influence therapeutic responsiveness, sustained minimal residual disease negativity, and long-term outcomes for patients undergoing autologous stem cell transplantation. In our exclusive interview, Dr Phull reviewed findings from a translational study that longitudinally profiled the fecal microbiome of patients with newly diagnosed myeloma, highlighting the significant post-transplant depletion of beneficial short-chain, fatty acid–producing organisms and its association with inferior progression-free survival. She also outlined supportive laboratory and in vivo data demonstrating the antitumor effects of butyrate and discussed how microbiome profiling may serve as both a predictive biomarker and a potential therapeutic target. Additionally, Dr Phull explored how dietary patterns, lifestyle factors, and antibiotic stewardship may contribute to preserving gut microbial health, and she emphasized the growing need for prospective studies to clarify how these interventions could enhance treatment outcomes for patients with active myeloma and precursor conditions such as monoclonal gammopathy of undetermined significance and smoldering myeloma.

What if prostate cancer surgery meant fewer incisions, faster recovery, and more precise cancer control? Today I'm joined by Dr. Michael D. Stifelman, Chair of Urology at Hackensack University Medical Center and a pioneer in robotic surgery with 4,000+ robotic procedures. We unpack how single-port robotics, real-time margin assessment, and AI are reshaping outcomes—while protecting continence and erections.Dr. Stifelman traces robotics from the early-2000s “pioneer phase” (and heavy skepticism) to today's standard of care, explaining why reproducibility, visualization, and tissue-sparing dexterity made the difference. We compare surgery vs. radiation (and focal therapies), when each shines, and why sequencing often matters—especially in higher-risk disease. He shares emerging tech like single-port prostatectomy, intra-operative margin evaluation (e.g., Histo-style scanning), quantitative surgical analytics, and even remote robotic assistance. We also talk “trifecta” outcomes, the role of genomics in Gleason 7 decision-making, and why lifestyle medicine and optimizing the tumor micro-environment go hand-in-hand with any treatment.Time-Stamped Highlights00:00 – Why fewer incisions + faster recovery are now real in prostate surgery05:40 – Work–life changes that improved health (sleep, exercise, biking)09:10 – Open vs. robotic: why reproducibility (teachability) matters11:05 – Robotics adoption curve: from early resistance to mainstream19:05 – Outcomes today: continence and erections after modern surgery20:10 – “Yes, I'm a surgeon—and here's my bias.” Radical honesty with patients22:05 – Offering the full menu: surveillance, focal (HIFU/cryotherapy), surgery, SBRT, proton25:40 – High-risk (Gleason 8–9): why surgery-first can preserve options & avoid long ADT34:00 – Dexterity & visualization: why robots spare nerves with less trauma35:10 – Real-time margin assessment during surgery to reduce positives40:00 – The “trifecta” (cancer control, continence, erections) and patient priorities42:10 – Genomics to risk-stratify Gleason 7 and guide surveillance vs. treatment45:00 – Future: nerve activation mapping & fluorescence to “light up” cancer46:10 – Single-port prostatectomy: smaller access, faster return of function (select patients)49:00 – Quantifying surgery with analytics; tele-mentoring & remote console potential52:30 – How to find Dr. Stifelman & closing advice

Dr. Roy Ligresti, chief of gastro-enterology at Hackensack University Medical Center in New Jersey tells Megan Lynchthat coffee is filled 'with a rich anti-oxident load,' but warns against a new trend of using the liquid in an enema.

Guest: Mutahar Ahmed, MD Optimizing urinary diversion and continence techniques is essential for improving patient outcomes and quality of life following surgery. Join Dr. Mutahar Ahmed as he provides expert guidance on improving success in conduits and neobladders in the operating room and beyond. Dr. Ahmed is the Director of the Center for Bladder Cancer at Hackensack University Medical Center as well as a Professor of Urology and the Director of the Minimal Invasive Robotic Oncology and Urology Fellowship Program at Hackensack Meridian School of Medicine. He also presented on this topic at the 2025 American Urological Association Annual Meeting.

Guest: Mutahar Ahmed, MD Optimizing urinary diversion and continence techniques is essential for improving patient outcomes and quality of life following surgery. Join Dr. Mutahar Ahmed as he provides expert guidance on improving success in conduits and neobladders in the operating room and beyond. Dr. Ahmed is the Director of the Center for Bladder Cancer at Hackensack University Medical Center as well as a Professor of Urology and the Director of the Minimal Invasive Robotic Oncology and Urology Fellowship Program at Hackensack Meridian School of Medicine. He also presented on this topic at the 2025 American Urological Association Annual Meeting.

In today's episode of Plugged In, host Chuck Hanna speaks with Kyle Tafuri, Vice President of Sustainability at Hackensack Meridian Health, about the organization's ambitious sustainability initiatives. Kyle shares perspectives on balancing long-term environmental goals with the immediate challenges of operating a healthcare system, emphasizing the importance of strategic partnerships, incremental progress, and innovative solutions like offsite solar, carbon capture, and geothermal energy. He also discusses Hackensack Meridian Health's proactive approach to supply chain sustainability, energy efficiency, and patient-centered environmental strategies.   You will want to hear this episode if you are interested in... The challenges of incorporating sustainability into healthcare operations (02:04) Implementing key energy efficiency and sustainability initiatives (06:24) How Hackensack measures its sustainability success (09:50) Balancing long-term sustainability goals with practical progress (14:50) How Hackensack is expanding sustainability efforts (18:39) For detailed show notes, click here. Connect with Kyle Tafuri  On LinkedIn Kyle Tafuri, Vice President of Sustainability at Hackensack Meridian Health, is not just a leader in healthcare sustainability – he's a visionary. For over a decade, Kyle has been instrumental in weaving sustainability into the very fabric of Hackensack Meridian Health (HMH), transforming the health system into an industry leader in environmental responsibility. Under Kyle's leadership, HMH and its hospitals were the first in the country to receive the Joint Commission Sustainability Certification. The flagship hospital, Hackensack University Medical Center, has been recognized as one of the top 25 green hospitals by Practice Greenhealth for nine consecutive years. All of HMH's hospitals are in the process of implementing 30 MW of on-site solar and battery storage, which is the most of any health system in the U.S. His dedication to green building, sustainable food practices, waste reduction, and responsible purchasing has set a new standard for healthcare institutions nationwide. Connect with Constellation Follow Constellation on LinkedIn  Follow Chuck Hanna on LinkedIn Learn more about Constellation sustainability solutions Connect with Smart Energy Decisions Smart Energy Decisions Follow us on LinkedIn Subscribe to Smart Energy Voices on Apple Podcasts, Google Podcasts, Android, Spotify, Stitcher, TuneIn Radio, aCast, PlayerFM, iHeart Radio If you're interested in participating in the next Smart Energy Decisions Event, visit smartenergydecisions.com or email our Community Development team at attend@smartenergydecisions.com

Claire L. Carter, Ph.D., is an Assistant Member of the Center for Discovery and Innovation; Assistant Professor of Pathology at Hackensack Meridian School of Medicine; and Co-Director of the Mass Spectrometry and Analytical Pharmacology Shared Resource at the NCI-designated Georgetown Lombardi Comprehensive Cancer Center.Dr. Carter completed her Ph.D. in Chemistry at the University of Birmingham, UK, under the supervision of Professor Josephine Bunch. She then moved to the US for a postdoctoral appointment at the University of Maryland Baltimore, where she worked on normal tissue radiation injury. At the Hackensack Meridian Center for Discovery and Innovation, Dr. Carter has built a translational pediatric neuro-oncology research program in partnership with Dr. Derek Hanson, Director of Pediatric Neuro-oncology, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center.Dr. Carter possesses a rare translational background that combines expertise in bioanalytical chemistry, clinical histopathology and biomedical science. Her group are using next generation imaging techniques to develop a deep understanding of the biological and transitional states of tumor cells as shaped by their spatiotemporal location within patient tumors and preclinical models. Their focus is on targeting lipid signaling and metabolism for less toxic and more efficacious treatments in highly aggressive pediatric brain tumors. In addition to using mass spectrometry imaging for intratumoral pharmacokinetic/pharmacodynamic (PK/PD) studies to identify more efficacious treatment regimens that can be rapidly translated into clinic gain.You can also get involved with the Gold Ribbon Kids Cancer Foundation or the National Pediatric Cancer Foundation through fundraising, volunteering, promoting awareness, or contributing to pediatric cancer research. Visit goldribbon-kids.org or nationalpcf.org for more informationTo contact Tiffany, please email info@goldribbon-kids.orgTo contact Kelly, please email kgoddard@nationalpcf.orgSupport the show

Today we're covering a topic that's notoriously painful: kidney stones. These little crystals can cause big problems, but thankfully, we have expert guidance to help us navigate the murky waters of kidney stone prevention and treatment. Joining us today is board certified Nephrologist of Hackensack University Medical Center and Palisades Medical Center, Dr. Nikhita Gadi, who's here to answer all our burning questions. So, whether you're currently nursing a kidney stone or just want to stay informed, grab a glass of water and get ready to learn.

In today's episode, we had the pleasure of speaking with Andre Goy, MD, about key updates from the 2024 ASH Annual Meeting. Dr Goy is physician in chief of Hackensack Meridian Health Oncology Care Transformation Services, as well as the chairman, chief physician officer, and chief of the Lymphoma Division at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey. In our exclusive interview, Dr Goy discussed top hematologic oncology research conducted by his colleagues at the John Theurer Cancer Center and his predictions for the future of the field in 2025 and beyond.

Eating disorders are not just about food; they're about control, fear, and deep-seated emotional pain. As parents, it's our instinct to protect and nurture, but recognizing the signs of an eating disorder can be incredibly challenging. According to a recent study, girls as young as 6 years old begin to worry about their weight, and by age 14, 60-70% are actively trying to lose weight. In this episode, we are joined by adolescent medicine experts who specialize in pediatric eating disorders: Jennifer Northridge, M.D., who leads the adolescent medicine program at the Joseph M Sanzari Children's Hospital at Hackensack University Medical Center, and Noor Al-Husayni, M.D., an attending physician in the program. We discuss the reasons behind the rising rates of eating disorders, how to identify early warning signs and effective treatment strategies.

In this "best-of" edition of the Healthcare Experience Matters Podcast, we are honored to present an episode that was released almost exactly one year ago to the day. Please enjoy this replay of one of our most popular episodes ever, featuring Ramonita Jiménez, DNP, MPA, RN, NEA-BC, Chief Nursing Officer at Hackensack University Medical Center, who joins us for this incredibly memorable discussion on retaining nurses.  Dr. Jiménez discusses the many ways medical institutions of all scopes and sizes can effectively address nurse retention challenges. Learn More: https://healthcareexperience.org/nurse-retention 

Ramonita Jiménez, DNP, MPA, RN, NEA-BC, Chief Nursing Officer with Hackensack University Medical Center is our guest on the Healthcare Experience Matters Podcast this week for timely conversation on leadership empowerment. Conducting today's interview as our special guest host is Kathleen Lynam, RN, MPA, an Executive Coach and Senior Advisor with the Healthcare Experience Foundation (HXF). Learn more: https://healthcareexperience.org/leadership-empowerment 

NotesIt is estimated that approximately one in every three children will receive treatment for an ear infection before they turn three years old. Ear infections are the most common reason young children visit their doctor. And, about one in every fifteen children will have ear tubes inserted by the age of three.In this episode, we are joined by Michael Chee, M.D., pediatric otolaryngologist at Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center., to shed some light on ear infections, eardrum ruptures, and when ear tubes are the best solution.

Unintentional injuries and accidents are the third leading cause of death in the U.S., according to the CDC.Joined by trauma surgeon Ibrahim Abd El-Shafy, M.D. and trauma nurse Mackenzie Murphy, both from Hackensack University Medical Center, we look at the most common causes of injury and how we can take proactive steps to keep ourselves and our loved ones safe. From falls, poisoning, and drowning to motor vehicle crashes, we cover it all and provide practical strategies for avoiding trips to the emergency room.

YouTube Video Episode Available! Gulfcoast Ultrasound Institute YouTube Channel On this episode of The Sonography Lounge hosts Lori and Trisha sit down with Dr. Charlotte Derr & Dr. Allyson Hansen to discuss the GUARD Protocol (Gastric Ultrasound for Aspiration Risk Determination). With the increased use of GLP-1 Agonists (Semaglutide, with brand names such as Ozempic, Wegovy, Rybelsus, Etc) for both diabetes and weight loss, there has been an increased number of aspirations in patients undergoing procedures. One of the effects of GLP-1 agonists is delayed gastric emptying which keeps patients feeling "full" thus reducing the desire to eat and overall caloric intake and blood sugar variations. Typically 6-8 hours not eating is enough time for a patient about to undergo an elective procedure to digest and empty their stomachs thus reducing the risk of aspiration while under anesthesia. With patients on GLP-1 agonists, we are seeing gastric contents remaining for several days after the last meal which can increase the risk of aspiration.  Dr. Derr and Dr. Hansen, discuss how they are using ultrasound and the GUARD protocol to determine the volume of food in a patient's stomach before elective and emergency procedures. This quick and simple bedside technique can drastically alter a provider's pre-procedure course of action.  CHARLOTTE DERR, MD, RDMS, FPD-AEMUS, FACEP Dr. Derr is the Professor of Emergency Medicine and the Fellowship Director of the Advanced Emergency Medicine Ultrasound Fellowship Program at the University of South Florida Morsani College of Medicine in Tampa, FL and serves as the Co-Medical Director at Gulfcoast Ultrasound Institute. She is a fellow of the American College of Emergency Physicians and is a registered diagnostic medical sonographer. She has also obtained the Focused Practice Designation in Advanced Emergency Medicine US from the ABEM. She has authored and co-authored numerous articles, book chapters, and other publications on ultrasound and lectures throughout the US and internationally on diagnostic ultrasound.    ALLYSON HANSEN, DO Dr. Allyson Hansen is the Ultrasound Director at the University of South Florida Emergency Medicine program. She received her education at the University of South Florida and Campbell University. Dr. Hansen completed her Hackensack University Medical Center residency and Emergency Ultrasound Fellowship at Tampa General Hospital. She is passionate about teaching and is an instructor at Gulfcoast Ultrasound Institute. Gulfcoast Ultrasound Institute: GUARD Protocol Blog GUARD Protocol YouTube Hot Tip USF HEALTH: GUARD protocol blog   Upcoming POCUS Courses @ Gulfcoast Ultrasound Institute CME and Cross training resources: Gulfcoast Ultrasound Institute (Training materials and programs): www.gcus.com   Certification Agencies: American Board of Emergency Medicine (ABEM): https://www.abem.org/public Sonographer / Physician: American Registry of Diagnostic Medical Sonography (ARDMS): www.ardms.org Physicians: Alliance for Physician Certification & Advancement (APCA): www.APCA.org Point of Care Healthcare Providers: Point of Care Certification Academy (POCUS): www.pocus.org Sonographer / Physician: Cardiovascular Credentialing International (CCI): www.cci-online.org  Find an accredited long-term Ultrasound Program: https://www.caahep.org/Students/Find-a-Program.aspx    

In a discussion with CancerNetwork® at John Theurer Cancer Center, Gregory Charak, MD, highlighted advancements in surgical treatment strategies for patients with colorectal cancer (CRC) as well as other ongoing challenges in the field. Specifically, Charak, a board-certified colorectal surgeon at Palisades Medical Center and Hackensack University Medical Center of Hackensack Meridian Health, described how minimally invasive strategies such as laparoscopic and robotic surgery have become more prevalent in the field, which have appeared to confer improvements in pain and length of hospital stay for patients. Although these minimally invasive techniques are typically preferred in this population compared with open surgery, Charak stated that he would still employ the latter depending on factors such as tumor size. Charak also discussed the rise in CRC incidence among younger populations, which has impacted how practices conduct screening. He highlighted that patients who are in their late 20s or 30s receive recommendations to undergo colonoscopy in the event of weight changes or blood appearing in their stool, noting that he would not hesitate to perform screening even if there's a small but real possibility of disease. Regarding other treatment modalities in this population, Charak emphasized the potential benefits of neoadjuvant therapy. Administering neoadjuvant treatment with agents including cytotoxic chemotherapy and immunotherapy, for example, may help achieve negative-margin resections, thereby yielding less morbidity for patients. “It's a very exciting time to be a surgical oncologist. [There are] tremendous new treatment modalities coming down the pike. Immunotherapy, in particular, is extremely exciting because it's such an elegant way to treat cancer: to harness and augment the body's own defense system to eliminate a cancer rather than using cytotoxic chemicals or invasive surgery,” Charak said. “It's a beautiful thing. If we can get it to apply to more and more tumors and figure out how to make it work, it couldn't be more exciting.” 

In this edition of “Lessons in Leadership,” Steve Adubato and Mary Gamba talk with Ramonita Jimenez, RN, DNP, Vice President, Chief Nursing Officer, Hackensack University Medical Center and Michael D. Stifelman, MD, Professor and Chair Urology, Hackensack Meridian School of Medicine about the keys do doctor / nurse communication, leadership and collaboration. Then, Steve is … Continue reading Lessons in Leadership: Dr. Michael Stifelman and Dr. Ramonita Jimenez / Krishna Powell

Join for the third episodes in the Association of Out Surgeons & Allies (AOSA) series for a discussion on LGBTQIA+ healthcare providers and their patients.   Host:  Nina Clark, MD  Guests:  - Andrew Schlussel, DO, Colorectal and General Surgeon, Charlie Norwood VA Medical Center - Dr. James Taylor, Assistant Professor of Colorectal Surgery at Montefiore Medical Center - Dr. Alex Bonte, General Surgery PGY4 at Hackensack University Medical Center in Hackensack NJ.  - Dr. Paige Tannhauser, General Surgery PGY3 (completed) at Allegheny General Hospital in Pittsburgh PA, and currentlyfinishing up a post-doctoral research fellowship at the University of Virginia. Learn more and get involved with AOSA: https://www.outsurgeons.org Twitter/X: @OutSurgeons Resources Mentioned This Episode:  "Gender Unicorn" schema for terminology: https://transstudent.org/gender/ LGBTQ Healthcare Directory: https://lgbtqhealthcaredirectory.org/ CDC Recommendations in LGBTQ Health: https://www.cdc.gov/lgbthealth/index.htm WPATH Resources: https://www.wpath.org/  Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen/

Our guest is Dr. Nitin Yerram, director of urologic research and director of urologic oncology at Hackensack University Medical Center, in the department of urology. He talks with us about what you should know about clinical trials so patients and caregivers can be more informed. Short on time? Use the below timestamps to jump to any topic section: 0:41 - Introduction 1:00 - What is a clinical trial? 2:13 - Phase of a clinical trial 5:20 - Could clinical trials offer better care than standard treatments? 6:48 - Who should take part in a clinical trial? 8:12 - Benefits of taking part in a clinical trial 9:54 - Positive feedback about clinical trials 12:14 - Questions for patients and caregivers to ask their doctor 13:23 - Privacy and rights of the patient during a clinical trial 16:10 - Fees to know about with clinical trials 17:25 - Where to find resources about clinical trials 19:21 - Final thoughts Supported by an independent educational grant from Merck. For more information, please visit www.UrologyHealth.org and don't forget to subscribe to our free digital magazine, UrologyHealth extra® at https://www.urologyhealth.org/uhe. **** March 28, 2024

When expecting a baby, among the flurry of decisions to be made, choosing where to deliver stands out as one of the most significant. It's a choice that goes beyond mere geography or convenience; it's about where you'll welcome your child into the world and the first level of care both of you will receive. It's about safety, support, and a positive birth experience. Today, we're spotlighting Hackensack University Medical Center (HUMC) as an exemplary choice for families looking to ensure the best start for their newborns. The Importance of the Right Location The location you choose for delivery impacts the medical care quality, emotional support, and the array of services available to you and your baby. A hospital equipped with top-tier facilities, specialized care, and a nurturing environment can make a significant difference in your childbirth experience. It's not just about the immediate moments post-birth but also about the comprehensive care leading up to and following this life-changing event. Why Hackensack University Medical Center Stands Apart Magnet Hospital Recognition: A Mark of Nursing Excellence HUMC isn't just any hospital; it's recognized as a Magnet hospital. This prestigious designation is the gold standard for nursing excellence and quality patient care. It signals a supportive environment not just for patients but for the medical professionals dedicated to your care, ensuring that you receive the best possible support during this critical time. Level III NICU: Ready for Every Possibility Babies don't always arrive as expected, and some need a little extra help getting started. HUMC's Level III Neonatal Intensive Care Unit (NICU) is equipped for a high level of neonatal care. This means that even the smallest or sickest of newborns receive top-notch, specialized care, offering peace of mind that, should your baby need it, the best possible support is right there. All Private Rooms: Comfort, Privacy, and Bonding The benefits of all private rooms cannot be overstated. Privacy during these first moments can significantly impact a mother's stress levels and overall recovery. HUMC offers this serenity, facilitating a peaceful environment where families can bond with their new arrivals without the intrusion of a shared space. Lactation Consultations 7 Days a Week: Support for Breastfeeding Mothers Breastfeeding, while natural, can come with its set of challenges. HUMC's commitment to lactation consultations seven days a week ensures that mothers receive the support and guidance they need, promoting successful breastfeeding practices and addressing any concerns promptly. High-Level Experience: A Team You Can Trust At HUMC, you're in good hands. The hospital prides itself on its highly experienced team of obstetricians, pediatricians, nurses, and other healthcare professionals who bring a wealth of knowledge and compassion to their roles. This high level of experience means that expectant parents can relax, knowing they're supported by some of the best in the field. Choosing where to give birth is a pivotal decision for expecting families. It's about more than just the physical location—it's about the care, the support, and the environment that will surround you and your baby during one of life's most momentous occasions. Hackensack University Medical Center stands out as a beacon of excellence in this regard, offering everything from unparalleled medical care to the peace and privacy families deserve. As you consider your options, remember the difference the right location can make—not just for the birth itself but for the lifelong memories it will help create.   Your feedback is essential to us! We would love to hear from you. Please consider leaving us a review on your podcast platform or sending us an email at info@maternalresources.org. Your input helps us tailor our content to better serve the needs of our listeners. For additional resources and information, be sure to visit our website at Maternal Resources: https://www.maternalresources.org/. You can also connect with us on our social channels to stay up-to-date with the latest news, episodes, and community engagement: Twitter: https://twitter.com/integrativeob YouTube: https://www.youtube.com/maternalresources Instagram: https://www.instagram.com/integrativeobgyn/ Facebook: https://www.facebook.com/IntegrativeOB Thank you for being part of our community, and until next time, let's continue to support, uplift, and celebrate the incredible journey of working moms and parenthood. Together, we can create a more equitable and nurturing world for all.

On Thursday, Fulton County District Attorney Fani Willis testified at a hearing about her prosecution of former President Donald Trump and many others connected to efforts to overturn the 2020 election. Trump's attorneys are calling for Willis to be removed from the case after she allegedly had a romantic relationship with a special prosecutor she hired to help lead her investigation. FOX News Sunday anchor Shannon Bream joined the Rundown to discuss this case and others that former President Trump is facing. Later, she explains National Security Advisor Jake Sullivan's comments about a pressing national security threat and Russia's reported pursuit of nuclear weapons in space. February is American Heart Month, and doctors across the nation are raising awareness about the importance of cardiovascular health. Over the past decades, heart disease and related ailments have been on the rise in the United States, bringing heart health to the forefront. Associate Director for Structural and Congenital Heart at Hackensack University Medical Center, Dr. Craig Basman, joins the Rundown to discuss the basics of understanding what makes a healthy heart, how to monitor your cardiovascular wellness, and what things to avoid if you are predisposed to heart conditions. Don't miss the good news with Tonya J. Powers. Plus, commentary by financial expert and author of “Know Yourself, Know Your Money,” Rachel Cruze. Photo Credits: Associated Press Learn more about your ad choices. Visit megaphone.fm/adchoices

On Thursday, Fulton County District Attorney Fani Willis testified at a hearing about her prosecution of former President Donald Trump and many others connected to efforts to overturn the 2020 election. Trump's attorneys are calling for Willis to be removed from the case after she allegedly had a romantic relationship with a special prosecutor she hired to help lead her investigation. FOX News Sunday anchor Shannon Bream joined the Rundown to discuss this case and others that former President Trump is facing. Later, she explains National Security Advisor Jake Sullivan's comments about a pressing national security threat and Russia's reported pursuit of nuclear weapons in space. February is American Heart Month, and doctors across the nation are raising awareness about the importance of cardiovascular health. Over the past decades, heart disease and related ailments have been on the rise in the United States, bringing heart health to the forefront. Associate Director for Structural and Congenital Heart at Hackensack University Medical Center, Dr. Craig Basman, joins the Rundown to discuss the basics of understanding what makes a healthy heart, how to monitor your cardiovascular wellness, and what things to avoid if you are predisposed to heart conditions. Don't miss the good news with Tonya J. Powers. Plus, commentary by financial expert and author of “Know Yourself, Know Your Money,” Rachel Cruze. Photo Credits: Associated Press Learn more about your ad choices. Visit megaphone.fm/adchoices

On Thursday, Fulton County District Attorney Fani Willis testified at a hearing about her prosecution of former President Donald Trump and many others connected to efforts to overturn the 2020 election. Trump's attorneys are calling for Willis to be removed from the case after she allegedly had a romantic relationship with a special prosecutor she hired to help lead her investigation. FOX News Sunday anchor Shannon Bream joined the Rundown to discuss this case and others that former President Trump is facing. Later, she explains National Security Advisor Jake Sullivan's comments about a pressing national security threat and Russia's reported pursuit of nuclear weapons in space. February is American Heart Month, and doctors across the nation are raising awareness about the importance of cardiovascular health. Over the past decades, heart disease and related ailments have been on the rise in the United States, bringing heart health to the forefront. Associate Director for Structural and Congenital Heart at Hackensack University Medical Center, Dr. Craig Basman, joins the Rundown to discuss the basics of understanding what makes a healthy heart, how to monitor your cardiovascular wellness, and what things to avoid if you are predisposed to heart conditions. Don't miss the good news with Tonya J. Powers. Plus, commentary by financial expert and author of “Know Yourself, Know Your Money,” Rachel Cruze. Photo Credits: Associated Press Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast episode we want to introduce you to our BCEN Friend George Olschewski. George Olschewski started out in healthcare as an EMT in 1993 and finished an English degree with a minor in journalism before going back for his nursing degree. Since 1998 George worked in the hospital from the intermediate and step down units to the ED at the Level One trauma center-University Hospital in Newark, New Jersey. It was there that George became a founding member of the Critical Care Transport Team at the trauma center. George continues to serve in both specialties of EMS and transport nursing at Hackensack University Medical Center's specialty care transport unit and Angel Midflight's aeromedical flight team. In addition to his CTRN, George holds the TCRN, CEN and TCRN certification along with his certification as a Nationally Registered Paramedic. Come along as Janie Schumaker, Michael Dexter, and Hollye Briggs talk with George about his career in transport nursing and recent nomination and selection for a BCEN award.  Come join in on this celebration conversation. This episode is called “Not all Heroes are in Comic Books: Spotlight on the 2023 Distinguished CTRN Award Winner.” George can be reached on LinkedIn @GeorgeOlschewski.

Ramonita Jiménez, DNP, MPA, RN, NEA-BC, Chief Nursing Officer with Hackensack University Medical Center joins our Healthcare Experience Matters Podcast this week. We are honored to have Dr. Jiménez join our weekly program to discuss the multitude of innovative ways medical institutions of all scopes and sizes can effectively address nurse retention challenges. Learn More: https://healthcareexperience.org/nurse-retention 

On this week's "2 Giant Goofballs: A New York Giants Podcast" hosted by Drew and Rob, the New York Giants execute a significant trade, sending defensive tackle Leonard Williams to the Seattle Seahawks. In exchange, they secure a 2024 second-round pick and a 2025 fifth-round pick, with potential salary considerations. This trade is a remarkable feat for the Giants, considering Williams' age and complex contract. The podcast also explores potential trades for players like Xavier McKinney, Paris Campbell, and Adoree Jackson, with running back Saquon Barkley off the table.In quarterback news, the podcast celebrates the return of Daniel Jones, who has been medically cleared for contact. This timely development is crucial, as backup Tyrod Taylor sustained a rib injury during the New York Jets game, leading to his hospitalization. The hosts discuss the ins and outs of NFL player statuses and share why Jones couldn't be activated on game day despite his clearance. The good news is that Jones will be back in practice soon.The "2 Giant Goofballs" hosts also provide an update on Taylor's condition, revealing that he has been discharged from the Hackensack University Medical Center. While specific details about his rib injury are still pending, Taylor's history with fractured ribs adds concern. In this context, Jones' clearance is a relief, potentially allowing him to start against the Las Vegas Raiders.Furthermore, the Giants bolster their defense by signing free agent cornerback Stanley Thomas-Oliver, who spent the last three seasons with the Carolina Panthers, primarily on injured reserve and the practice squad. This signing adds depth to the team's defensive ranks, particularly on special teams. For more in-depth discussions and analysis, tune in to "2 Giant Goofballs: A New York Giants Podcast."#giants #nygiants #nflPMOFM MediaPlay Me or Fade Me Daily Sports Betting PicksSupport the showAll Episodes are shot LIVE with fan interactions on Youtube, Facebook, Twitter, & TwitchSponsor the show at: https://www.buymeacoffee.com/2giantgoofballsInterested in starting a podcast. We recommend using buzzsprout: https://www.buzzsprout.com/?referrer_id=2012368

Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College discusses Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes with Taya Glotzer, MD, FHRS, of Hackensack University Medical Center at Hackensack Meridian Health, and Rod S. Passman, MD, FHRS, of Northwestern University.   https://www.hrsonline.org/education/TheLead   Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Aboot, Phillips; Stocks (Privately Held): Atlas 5D   Contributor Disclosure(s): T. Glotzer: Honoraria/Speaking/Consulting Fee: Mayo Clinic, Medtronic, Boston Scientific, Abbot, Mediasphere Medical R. Passman: Honoraria/Speaking/Consulting Fee: Medtronic, Janssen Pharmaceuticals, iRhythm Technologies, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): AHA Foundation Award, Abbott Medical, NIH/NHLI, Apple Inc; Royalty Income: UpToDate, Inc.

In this latest episode of ASTCT Talks, Christina Cho, MD, interviews Lori Muffly, MD, MS. During the conversation, Dr. Muffly emphasizes the need for more randomized data in ALL treatment and addresses the unique challenges of treating young adults, including fertility preservation. Dr. Muffly also emphasizes the significance of measurable residual disease (MRD) monitoring using the clonoSEQ® Assay, offering valuable insights into leukemia care. About Lori Muffly, MD, MS Lori Muffly, MD, MS, an Associate Professor of Medicine at Stanford University, specializes in adult acute leukemia research, clinical trials, and hematopoietic cell transplantation. Her work focuses on improving cancer care access and reducing disparities in young adults with acute lymphoblastic leukemia. Dr. Muffly leads multiple health outcomes studies and clinical trials, including research on measurable residual disease, CAR T-cell therapies, and real-world outcomes for adult acute lymphoblastic leukemia patients. She has a history of successful collaboration with fellow researchers and is a sought-after national speaker on adolescent and young adult leukemia and cancer care access. About Christina Cho, MD Christina Cho, MD is a hematologist/oncologist specializing in adult stem cell transplantation and cellular therapy at Hackensack University Medical Center's John Theurer Cancer Center. Dr. Cho conducts clinical research on stem cell transplantation, including therapies for leukemia and sickle cell disease. She is an active member of the American Society of Hematology and the American Society for Transplantation and Cellular Therapy and currently serves as editor for ASTCT Nucleus.

It's been more than 35 years since Peter Kahan and Dr. Ravi Munver first met. Back then, they were a teacher and his student, respectively. These days, the two men remain connected, but their relationship has evolved — Munver is now a key member of Kahan's bladder cancer care team. “To have to have a somebody who really looks upon you as a friend as (your) doctor, (who) really can see you as more than just another patient is great,” said Kahan, who described his connection with Munver, a urologic oncologist and vice chair of the department of urology at Hackensack University Medical Center in New Jersey, as “completely” crucial to his cancer journey. “You know, there are a lot of physicians who are phenomenal,” said Munver. “But when you meet them, to them you're a patient, and they care for you as a patient. It's very different when you either have a personal relationship with a physician, or you have a physician who literally has a motto that says ‘I treat all of my patients like my friends and family,' meaning if Peter walked in the door or a family friend walked in the door or a distant family member walked in the door, I would treat them all exactly the same. One would not get more time or better treatment than another. So, when you have physicians that have that model where they treat every patient as if they were their own family member or friend, you just get a different feel flavor and level of care.” Kahan was Munver's honors physics teacher at the Dwight-Englewood school in northern New Jersey in 1987, where he noted that Munver was “one of my best students. … He was extremely meticulous and careful in his work.” “Of all the sciences that I took — biology, chemistry, physics — physics really came easy to me, because it was math-based,” Munver said. “And I just remember obviously trying to do well in the class, but also enjoying the material. You have a great teacher, a teacher who teaches the material, who loves the material and has a passion for it, it makes that class that much easier and more fun and enjoyable, especially when you're first semester senior applying to college. And once I'd gotten into college, obviously, it was just a continuation of just more fun and learning. So, I really enjoyed class and I think what I remember most about it was it was a topic that was easy for me but enjoyable and very different from all of the other natural sciences.” The two men re-connected years later at a memorial service for a former teacher at Dwight-Englewood. Kahan, retired from teaching and living in upstate New York, discovered blood in his urine in 2019, and he subsequently received a diagnosis of high-grade non-muscle invasive bladder cancer from his local urologist. Treatment with the immunotherapy bacillus calmette-guerin (BCG) and the chemotherapy mitomycin inserted directly into the bladder followed. When his cancer recurred, Munver's doctors recommended he seek a cystectomy, or removal of the bladder and prostate, at Memorial Sloan-Kettering Cancer Center in New York City. Kahan reached out to Munver, looking for a second opinion. “As director of minimally invasive and robotic urologic surgery, I'm always looking at novel techniques, novel therapies that can offer patients good results, as well as a great quality of life,” said Munver. “And when Peter had told me about the traditional therapies that were being used, we use them as well. We use BCG. … When BCG fails, many urologists will jump to the next step, which is removal of the bladder. And that's what I learned in residency 22 years ago, and that's what people learned 30 years ago, and that's what people learned 50 years ago, it was that was the only algorithm. “However, a lot has changed, and I wanted to make sure that if he needed his bladder out, that (that) was the right thing to do. And it didn't have to be (done by) with me with robotic surgery, it could have been at any other institution of his choice. But at least I wanted to offer him a second opinion from someone who is in the academic space and knows all of the latest therapies out there.” Munver surgically removed the tumor and treated him with the immunotherapy combination of BCG and interferon. When the tumor returned, Hackensack had received approval for the novel chemotherapy drug combination of gemcitabine and docetaxel, administered in liquid form directly into the bladder. “In combination, the two medicines would really have a cancer cell destroying effect, and the clinical trials have been going on for years but we weren't able to accrue enough patients across the country and across the world to really see a demonstrable effect, we needed at least several year(s' of) data to be able to say, ‘Yes, this works compared to our traditional therapies,'” Munver said. “It's a massive undertaking to bring a new therapy to our patients, and we'd been working on it for months,” Dr. Nitin Yerram, director of urologic research at Hackensack, said in a statement. “Right when we were about to go live, Peter was looking for options.”  Studies have shown that up to half of patients respond to this novel therapy and are able to avoid surgery, Yerram said.  Kahan began treatment with the chemotherapy combination in January 2022, and he tells CURE® it has been approximately a year and a half since any tumors were found, through florescence in situ hybridization (FISH) tests, which check for chromosomal multiplications, have come back positive. “It's not necessarily that there are cancer cells, but there are cells that have a tendency to increase their proliferation. And we often see those in cancer cells,” Munver said. “We have several patients who are on this therapy right now, and several of the patients do have a positive urine test, but there's visibly no evidence of tumor I can see,” said Munver. “And I can see tumors as small as one to two millimeters. … As I mentioned to Peter, if the tumors return, basically the bladder cancer will declare itself and to this point, it is not, and we are just monitoring him very closely. And you know, we cross our fingers and hope that this therapy keeps him with a really good quality of life for many years to come.” In this episode of the “Cancer Horizons” podcast, Kahan and Munver speak with CURE about the importance of their friendship and their decision to embrace a new treatment option. For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

  “I think the take-home message here, though, is to have very specific guidelines at your institution to manage both CRS and ICANS. The protocols should be readily available to all practitioners who may participate in the care of these patients,” ONS member Phyllis McKiernan, MSN, APN, OCN®, advanced practice provider at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS. McKiernan's and Taylor's conversation centered around the nurse's role in recognizing and managing toxicities related to CAR T-cell therapy for hematologic malignancies, specifically ICANS and CRS, which was an educational priority that ONS members identified during two ONS focus groups on the topic in March 2023. McKiernan was one of the content experts for those focus groups.  This podcast episode is produced by ONS and supported by funding from Janssen Oncology/Legend Biotech. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod   Licensed under Creative Commons by Attribution 3.0    Episode Notes  NCPD contact hours are not available for this episode.  Oncology Nursing Podcast episodes: Oncologic Emergencies 101 series Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment Episode 1: Experiences With CAR T-Cell Therapy ONS Clinical Practice Resources: Chimeric Antigen Receptor T-Cell Therapy: A Timeline of Events and Adverse Events Cytokine Release Syndrome ONS Clinical Update: Focus on Clinical Experiences With CAR T-Cell Therapy ONS course: Nursing Considerations for CAR T-Cell Therapy for Patients With Hematologic Malignancies: Patient Education and Symptom Management ONS Huddle Card™️: Cytokine Release Syndrome ONS Immuno-Oncology Learning Library ONS videos: CAR T-Cell Therapy Cytokine Release Syndrome American Cancer Society American Society for Transplantation and Cellular Therapy Grading Scale for CRS and ICANS Leukemia and Lymphoma Society  Multiple Myeloma Research Foundation  National Institutes of Health's National Cancer Institute Risk Evaluation and Mitigation Strategies   To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.   To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.   Highlights From Today's Episode  “All symptoms need to be investigated fully to determine their cause and thus the best management strategy and not just simply assume that they're related to CAR T.” Timestamp (TS) 9:21   “Accurate grading is really crucial to ensure that the toxicities are identified and managed consistently across the institution.” TS 10:52  “Once the patient shows signs and symptoms of neurotoxicity, they should have a comprehensive neurologic examine, and that should include, a neurology consult, maybe imaging, such as an MRI or CT, and perhaps even a lumbar puncture.” TS 14:12  “Letting patients and their families know what next steps are can alleviate anxiety and give the patients the confidence that the medical team is familiar with these toxicities. And let them know that these toxicities are expected and that there are protocols in place to manage these symptoms.” TS 22:56  “I think that some patients, and even healthcare professionals, who aren't familiar with CAR T believe that the toxicities are always severe and always irreversible. When, in reality, most of the toxicities are mild and managed with minimal intervention or even just supportive care.” TS 23:55   “Early detection, consistent grading, vigilant monitoring, and standardized care plans are crucial to the success of any CAR T program and can also help reduce the risk of the severe adverse effects and hopefully improve outcomes for our patients.” TS 30:26 

Gary Small, MD, is Chair of Psychiatry at Hackensack University Medical Center. Dr. Small is a co-inventor of the first PET scanning method that provides images in living people of the physical evidence of Alzheimer's disease. In addition to testing compounds that may benefit cognitive abilities and possibly delay the onset of Alzheimer's disease symptoms, Dr. Small has studied and developed lifestyle and memory training programs for improving cognition and healthy aging. Dr. Small has authored over 500 scientific works and received numerous awards and honors, including the American Psychiatric Association's Weinberg Award for Excellence in Geriatric Psychiatry. Scientific American magazine named him one of the world's top 50 innovators in science and technology. He is the author of 12 popular books, including The New York Times bestseller, The Memory Bible.Sponsor: www.SeniorCareAuthority.com

Lauren talks with Dr. Gary Small, Chair of Psychiatry, Hackensack University Medical Center and Behavioral Health Physician in Chief, Hackensack Meridian Health. They address how to slow or delay the onset of dementia symptoms through lifestyle changes, but also how to manage dementia in the family and how it affects all family members.

Did you know about 50 million Americans live with some form of chronic pain? And not surprisingly celebrities including Paula Abdul, George Clooney, and Lady Gaga are among them. We sit down with Patrick Roth, M.D., chairman of Neurosurgery at Hackensack University Medical Center, who offers insight on some of the common questions about chronic pain.

Dr. Gary Small, former Director of UCLA's Longevity Center and currently Behavioral Health Physician-in-Chief at Hackensack Meridian Health, believes lifestyle choices can eclipse genetics to stymie Alzheimer's disease. Genetics influences cognitive health, Dr. Small acknowledges, but physical and mental exercise, managing stress and eating well can counteract the disease as individuals age. Even if people are at genetic risk, their behavior and length of life will determine if they get the disease, he says. Dr. Small is sanguine about the future, as studies show that lifestyle changes do lower the rate of contracting Alzheimer's. The high hurdle to cross, he concedes, is motivating people — in a pill-dependent society — to live healthier lives. Nationally renowned psychiatrist Gary W. Small, M.D., joined Hackensack Meridian Health as its Behavioral Health Physician-in-Chief on November 1, 2020. In this newly created position, Dr. Small oversees all professional and administrative activities within the behavioral health care transformation service at Hackensack Meridian Health, as well as serving as Chair of Psychiatry at Hackensack University Medical Center.  Prior to joining Hackensack Meridian Health, Dr. Small was a professor of psychiatry and biobehavioral sciences, Parlow-Solomon professor on aging at the David Geffen School of Medicine at UCLA, director of the Division of Geriatric Psychiatry at the Semel Institute for Neuroscience & Human Behavior and director of the UCLA Longevity Center.  Dr. Small is known nationally and internationally for his public work in promoting the practice of psychiatry and innovative research on brain health and aging. Dr. Small has authored more than 500 scientific publications as well as the international best-seller, The Memory Bible. Small's research has been featured in The New York Times, Wall Street Journal, London Times, Washington Post, Time Magazine, and Newsweek. Dr. Small's media links-  Website: htthttp://drgarysmall.com/ Facebook: https://www.facebook.com/DrGarySmallFanPage/ Twitter:  @drgarysmall Thank you to our Cutting Edge Health supporters: CZTL Methylene Blue Get a $10 discount by using this link: https://cztl.bz?ref=3OqY9 on an order of $70 or more OR use this discount code at checkout: jane10 Renue by Science: 10% off NMN https://renuebyscience.com/product/pure-nmn-sublingual-powder-30-grams/ Enter jane10 at checkout for 10% off.   Cutting Edge Health podcast website:  https://cuttingedgehealth.com/   Cutting Edge Health Social and YouTube: YouTube channel: https://www.youtube.com/channel/UCQj21tuf2rxidc8Kg8A5_NQ Instagram - https://instagram.com/cuttingedgehealthpodcast Facebook -  https://www.facebook.com/Cutting-Edge-Health-Podcast-with-Jane-Rogers-101036902255756   Please note that the information provided in this show is not medical advice, nor should it be taken or applied as a replacement for medical advice. The Cutting Edge Health podcast, its employees, guests and affiliates assume no liability for the application of the information discussed. Special thanks to Alan, Maria, Louis and Nicole on the Cutting Edge Health team!

Building a family business is tough, and handing over the reins of a family business can be even more challenging. Join host Hanna Hasl-Kelchneras she welcomesVincent Curatola, who shares some practical tips for navigating it successfully and pr otecting your family legacy along the way. Hear his remarkable story. WHAT YOU'LL DISCOVER ABOUT FAMILY BUSINESS: The backstory of his 3-generation family business. The perils of fast money. How to protect the legacy of your family business. The key to business sustainability. The story of the Wall Street trader. The impact of his sudden celebrity on the family business. And MUCH more. GUEST:Vincent Curatola is a Commissioner on The New Jersey Hall of Fame, appointed by New Jersey Governor Chris Christie. Vincent also served on the Governor's transition team. For the past 10 years, Vincent has also served as a member of the Foundation Board at Hackensack University Medical Center in New Jersey. If his name has a familiar ring, there's a reason for it. Vincent Curatola is also an accomplished actor. If you're a fan of the award-winning HBO drama, The Soprano's you'll remember him in his co-starring role as Johnny "Sack” Sacramoni. You've probably also seen him guest star on more than a few primetime network series including  Third Watch, Law & Order, Monk, Life on Mars, Person of Interest, BlackList, The Good Wife and Law & Order SVU where he regularly appears as Judge Al Bertuccio. On the big screen, he's co-starred with Brad Pitt and James Gandolfini in the crime thriller, Killing Them Softly. He's also played Boston Mayor Minnino in Patriot's Day with Mark Wahlberg, which was aired in  theaters at the end of 2016. But, even if you did recognize his name, you probably didn't know that he was a successful entrepreneur long before we saw that piercing look of his and heard that distinctive voice on camera. Yes, indeed!  Vincent has experienced firsthand what it's like to build a family business from the ground up and to successfully transition it.   RELATED RESOURCES:http://vincentcuratola.com/ (Contact Vincent) and connect with him https://twitter.com/vincentcuratola (Twitter). Also connect with http://acuratola.com/ (his family business).

Sponsored by Kettenbach Dental.  Contact: (877) 532-2123 Website: www.kettenbach-dental.us Webshop: www.kettenbachusa.com   Dr. Rizzo specializes in family and cosmetic dentistry. He attended the University of Medicine and Dentistry, where he attained his Doctorate of Dental Surgery Degree. He remained in New Jersey to complete his residency at Hackensack University Medical Center before beginning his practice in 1994. He is currently the Assistant Director of Dental Services at Hackensack Meridian Health Services. Dr. Rizzo is dedicated to providing premium care to his patients. He is aware of changes and advancements in both cosmetic and family dentistry and is committed to delivering state-of-the-art care to his patients. Dr. Rizzo is a proud member of the American Dental Association, as well as local professional organizations, such as the New Jersey Dental Association and the Bergen County Dental Society. When Dr. Rizzo is away from the office, he can be found fishing, hiking, or simply enjoying the great outdoors. He is also a musician and artist, and he enjoys fine art.   FFS Podcast Promotional Links:  ONLY $397: Dental Membership Master Course with Dr. Chris Phelps www.membershipmastercourse.com Dental Membership Direct www.dentalmembershipdirect.com Dental Financing Direct www.dentalfinancingdirect.com   About Dr. Sonny Spera Dr. Sonny Spera graduated from Union Endicott High School in 1981. With a four-year basketball scholarship he graduated from Syracuse University in 1985; majoring in Chemistry and Psychology. He was a member of the Sigma Alpha Mu fraternity. He was also the co-captain of the 1984-1985 Syracuse basketball team. Dr. Spera graduated from SUNY Buffalo Dental School in 1989 in the top 10% of his class. At SUNY Buffalo Dental School he was a member of the Omicron Kappa Upsilon Honorary Society. He was also UB Graduate Assistant Basketball coach.  Dr. Spera has been in private practice since 1989 and is a member of the American Dental Association, the New York State Dental Association, the Sixth District Dental Society and the Broome County Dental Society. He is also a member of the International Association of Orthodontics, the BC Dental Society and the BCDS Study Club. Away from the office, he volunteers with several community organizations, including the Elks Club, the Son's of Italy, the STNY Flyers, the Academy of General Dentistry, and the Basketball Coaches Association of New York. He is the founder and president of ME Hoops Inc. Dr. Spera currently resides with his wife Angela, whom he met at Syracuse University, and their three children, Marcus, Erica, and Carla. In his spare time, he enjoys spending time with his family, basketball, golf, music and movies. 607-624-2962 (Cell) Sonnyspera@gmail.com Www.progressivedentalny.com   Do you have a FFS practice? Would you like to be interviewed? Fill out the FFS Stories request form here: https://goo.gl/forms/7TaUF9Nqi49l1RFF2

It has been well over two years since COVID-19 was declared a pandemic and with that brought a year of loss, separation, anxiety, and uncertainty. Eventually, the physical stress of the infection might end, but for some, the emotional scars from the pandemic can last for months and years, often in the form of post-traumatic stress disorder (PTSD). We sit down with Dr. Gary Small, a behavioral health physician and chief and psychiatrist with Hackensack University Medical Center to talk through what this might mean for our community's mental health in the future.

Will Smith shared his colonoscopy with the world via a vlog to help promote colorectal cancer screenings. We brought in Rosario Ligresti, M.D. a gastroenterologist from Hackensack University Medical Center to talk us through this important screening.

A racing heart can make anyone nervous, including actress La La Anthony. We brought in Taya Glotzer, M.D. an Electrophysiologist from Hackensack University Medical Center to help us understand what a healthy heart rate looks like and how many beats are one too many.

For those who have running a marathon (or maybe just running in general) as a 2022 goal, we brought in Stephen Silver, M.D., Chief of Sports Medicine and Board-Certified Orthopedic Surgeon from Hackensack University Medical Center, to talk us through making that goal a reality.

Hans Schmidt, M.D., a bariatric surgeon from Hackensack University Medical Center, helps us understand how we can achieve our own personal weight loss goals this year.